Compare Axogen Inc (AXGN) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Axogen Inc trades at $48.85 (market cap $2.59B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: Axogen Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | FLRN | |
|---|---|---|
Market Cap | $2.59B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $48.48 | $30.86 |
52-Week Low | $14.16 | $30.65 |
Enterprise Value | $2.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.
Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
